Table 7 Amiodarone-monitoring parameters
PARAMETER MONITOREDFREQUENCY OF OCCURRENCE, %WHAT TO ORDER OR PERFORMHOW OFTEN
CNS (ataxia, dizziness)4-9Physical examinationEvery follow-up visit
Corneal deposits4-9Slit lamp examinationAnnually
Optic neuropathyUnknownOphthalmologic examinationBaseline, every 6-12 mo
Pulmonary toxicity2-17Chest x-ray scan, pulmonary function tests (and DLCO)Baseline, every 6-12 mo
Thyroid complications2-6Free T4 level, TSH levelBaseline, every 6-12 mo
Photosensitivity3-10History, physical examinationEvery follow-up visit
Blue discoloration of skin (Smurf or Avatar syndrome)< 9History, physical examinationEvery follow-up visit
GI (nausea, vomiting, anorexia)4-33Weight, physical examination, and historyEvery follow-up visit
Liver toxicity4-9AST, ALT, bilirubinBaseline, every 6-12 mo
  • ALT–alanine aminotransferase, AST–aspartate aminotransferase, CNS–central nervous system, DLCO–diffusing capacity of lung for carbon dioxide, GI–gastrointestinal, T4–thyroxine, TSH–thyrotropin.

  • Data from Jin and Kosar,4 Siddoway,34 and Pfizer Canada.35